Compare Abbott Laboratories (ABT) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs T-Mobile Us Inc — how do they compare? Abbott Laboratories trades at $95.34 (market cap $166.94B), while T-Mobile Us Inc trades at $181.28 (market cap $199.92B). The key difference: T-Mobile Us Inc is the larger of the two by market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | TMUS | |
|---|---|---|
Market Cap | $166.94B | $199.92B |
Sector | Health | Media |
52-Week High | $136.62 | $259.01 |
52-Week Low | $82.57 | $167.65 |
Enterprise Value | $193.69B | $317.61B |
Dividend Yield | 2.63% | 2.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
T-Mobile US (TMUS) trades at $184.73, up 4.06% on the day, with a bullish analyst consensus but bearish technical signals. The stock shows strong fundamentals with revenue growth to $88.31B in 2025 and a net income margin of 11.65%, though earnings have been mixed with a recent miss in Q4 2025. Recent news includes leadership changes and speculation about SpaceX's potential interest, while cash flow remains positive but projected to decline in 2026.
Outlook: TMUS offers growth potential with solid profitability and analyst targets near $256, but faces risks from competitive pressures and debt levels. Investment appeal hinges on execution amid sector volatility and macroeconomic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
